According to Rubin’s study, the combination therapy of vorinostat and buparlisib is the most effective for uterine carcinosarcoma patients harboring driver mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and phosphatase and tensin homolog (PTEN) among all combination strategies, and the treatment of buparlisib plus olaparib displayed strongest anti-tumor effects in the endometrial adenocarcinoma organoids organoid with mutations in PIK3CA and PTEN [94]. This evidence concerns the gene PTEN and endometrium adenocarcinoma.